Literature DB >> 1130720

Plasma protein binding of thiopental in patients with impaired renal or hepatic function.

M M Ghoneim, H Pandya.   

Abstract

Binding of thiopental to proteins in plasma from healthy, cirrhotic, and uremic subjects was studied using equilibrium dialysis. In plasma from healthy volunteers 28.0 plus or minus 0.9 per cent of thiopental was unbound. In plasma from patients with hepatic disease 53.0 plus or minus 2.1 per cent was unbound, while in patients with renal disease 55.7 plus or minus 1.5 per cent remained unbound. The decreased binding in uremia could not be explained completely by competitive displacement by nitrogenous end products or by hypoalbuminemia, although hypoalbuminemia may account for the decreased binding in cirrhotic patients.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1130720     DOI: 10.1097/00000542-197505000-00007

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  12 in total

Review 1.  Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).

Authors:  R Zini; P Riant; J Barré; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

2.  Pharmacokinetics of intravenous anaesthetics: implications for clinical use.

Authors:  M M Ghoneim; K Korttila
Journal:  Clin Pharmacokinet       Date:  1977 Sep-Oct       Impact factor: 6.447

Review 3.  Pharmacokinetics in intravenous anaesthetic practice.

Authors:  P Duvaldestin
Journal:  Clin Pharmacokinet       Date:  1981 Jan-Feb       Impact factor: 6.447

4.  Alteration of drug-protein binding in renal disease.

Authors:  M M Reidenberg; D E Drayer
Journal:  Clin Pharmacokinet       Date:  1984-01       Impact factor: 6.447

Review 5.  The binding of drugs to plasma proteins from patients with poor renal function.

Authors:  M M Reidenberg
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

Review 6.  Anaesthesia for patients with chronic renal disease.

Authors:  P H Weir; F F Chung
Journal:  Can Anaesth Soc J       Date:  1984-07

Review 7.  Pharmacodynamics and pharmacokinetics of thiopental.

Authors:  H Russo; F Bressolle
Journal:  Clin Pharmacokinet       Date:  1998-08       Impact factor: 6.447

Review 8.  Protein binding and kinetics of drugs in liver diseases.

Authors:  T F Blaschke
Journal:  Clin Pharmacokinet       Date:  1977 Jan-Feb       Impact factor: 6.447

9.  Plasma protein binding of azapropazone in patients with kidney and liver disease.

Authors:  E Jähnchen; K J Blanck; K H Breuing; H J Gilfrich; T Meinertz; D Trenk
Journal:  Br J Clin Pharmacol       Date:  1981-04       Impact factor: 4.335

Review 10.  Free drug concentration monitoring in clinical practice. Rationale and current status.

Authors:  C K Svensson; M N Woodruff; J G Baxter; D Lalka
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.